ArticleUpdates in surgery2026
Early prediction of severe acute cholecystitis using routine admission parameters: a study of 1,330 patients.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate routine clinical, demographic, and laboratory admission parameters as independent predictors of severe acute cholecystitis to facilitate early risk stratification. A total of 1,330 adult patients diagnosed with acute cholecystitis according to the Tokyo Guidelines 2018 (TG18) were analyzed in this single-center, retrospective study between 2019 and 2024. Patients were classified into mild/moderate (Group 1) and severe (Group 2) cohorts. Independent predictors of severe acute cholecystitis were determined using logistic regression and ROC analyses. To avoid incorporation bias, variables directly defining TG18 Grade 3 organ dysfunction were excluded from the multivariate models. Furthermore, internal validation was performed via bootstrap resampling (1000 iterations), and clinical utility was assessed using decision curve analysis (DCA). Group 2 (severe disease) comprised 12.9% (n = 172) of the cohort. The severe group was significantly older with a higher prevalence of diabetes. In multivariate analysis, the CRP/albumin ratio (CAR), age, diabetes mellitus, and hemoglobin level were identified as independent predictors The model demonstrated stable, moderate discriminatory power (AUC = 0.766). A Youden-derived CAR cut-off of > 1.10 significantly increased severe disease likelihood. DCA confirmed the model yielded superior net clinical benefit across relevant threshold probabilities. The combination of advanced age, diabetes mellitus, lower hemoglobin levels, and elevated CAR can provide a practical supportive framework for predicting severe acute cholecystitis. Within this multivariable approach, these routine admission parameters may enhance early bedside risk stratification and guide clinical vigilance alongside standard TG18 assessment.
Indexed as
Identifiers
42334811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.